Johnson & Johnson (J&J) has claimed that the first batches of its COVID-19 vaccine could be available as soon as in January.J&J said that the safety panel, called a Data and Safety Monitoring Board, has recommended that the drugmaker resume trial recruitment after finding no evidence that the vaccine caused the volunteer to fall ill.
The company expecting to resume its trial in US on Oct. 26 & 27 and remain on the track to produce data from the trial on the vaccines’ effectiveness by the end of 2020 or early 2021, J&J’s chief scientific officer Paul Stoffels said.
J&J is also in discussions with other regulators to resume a trial outside of the United States, the company said.
The drug maker’s announcement comes after the United States in the past two days registered its highest number of new COVID-19 cases – about 84,000 on October 23 and about 79,900 on October 24. The pandemic, which has caused about 225,000 US deaths and left millions of Americans jobless, remains front and centre in the presidential race.
Ruxandra Draghia-Akli, the company’s head of public health research and development, announced the same in a presentation at the World Health Summit.